Clinical significance of CA19-9 in mature cystic teratoma of the ovary.
- Author:
Young Ju CHA
1
;
Si Won JEON
;
Eun Ae SHIN
;
Eun Mi CHANG
;
Eun Kyoung SHIN
;
Mi Kyoung KIM
;
Woong JU
;
Seung Cheol KIM
Author Information
1. Department of Obstetrics and Gynecology, School of Medicine, Ewha womans University, Korea. onco@ewha.ac.kr
- Publication Type:Original Article
- Keywords:
CA19-9;
Mature cystic Teratoma;
Size;
Bilaterality
- MeSH:
Diagnosis;
Female;
Hand;
Humans;
Laparotomy;
Medical Records;
Ovary*;
Parity;
Sample Size;
Teratoma*;
Biomarkers, Tumor
- From:Korean Journal of Obstetrics and Gynecology
2007;50(9):1216-1222
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: The aim of this investigation was to analyze the association between ovarian tumor markers and the clinicopathologic features of ovarian mature cystic teratoma. METHODS: The medical records of 195 patients whose pathologic diagnosis were made as mature cystic teratoma after surgery from June, 2000 to July, 2006 at Ewha Womans University Mok-dong Hospital were reviewed. The proportions of elevation of each tumor marker were evaluated in all patients and CA19-9 which showed the greatest elevation rate was selected as a promising relevant tumor marker. The patients were alloted to either Group I showing elevated CA19-9 or Group II showing normal level of CA19-9. The relationship between CA19-9 level and demographic data or clinicopathologic features were investigated by usual statistical method. RESULTS: The mean age of all patients was 35.4+/-12.8, and the average size of tumor was 7.1+/-3.5cm. Bilaterality of the mature cystic teratoma was 12.8%. The proportion of the patients showing elevated levels was greatest in CA19-9 as 33.3% (65/195), compared with 12.0% in CA-125, 5.8% in CEA, 1.1% in AFP. Significant difference between Group I and Group II were found in age, parity, tumor size, and bilaterality. Bilaterality and tumor size were greater in Group I, and age and proportion of parous women were lower in Group I. On the other hand, the rate of ovarian torsion or laparotomy conversion showed no difference. Likelihood ratio for bilaterality which may be clinically used during surgical procedure were 2.2 for CA19-9 suggesting its potential role in gynecologic practice. CONCLUSION: This study shows that CA19-9 may be a useful tumor marker associated with tumor size and bilaterality in ovarian mature cystic teratoma. Further confirmative study with larger sample size is in need in order to establish its definite clinical role in ovarian mature cystic teratoma.
